Aflibercept Market Developments and Eylea HD FDA Approval Updates
Aflibercept continues to play a major role in the global ophthalmology therapeutics market, particularly in the treatment of retinal vascular diseases such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). Between 2023 and 2026, the market witnessed significant regulatory progress and product expansion driven by […]
Aflibercept Market Developments and Eylea HD FDA Approval Updates Read More »